# Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis

> **NCT01147666** · PHASE2 · COMPLETED · sponsor: **Kyntra Bio** · enrollment: 161 (actual)

## Conditions studied

- End Stage Renal Disease
- Anemia

## Interventions

- **DRUG:** Roxadustat
- **DRUG:** Epoetin Alfa
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01147666
- **Lead sponsor:** Kyntra Bio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-17
- **Primary completion:** 2012-10-15
- **Final completion:** 2012-10-15
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2022-01-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01147666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01147666, "Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01147666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*